[
  {
    "ts": "2026-01-09T01:44:24+00:00",
    "headline": "Johnson & Johnson reaches deal with US government to lower drug prices",
    "summary": "Jan 8 () - Johnson & ​Johnson ‌said on Thursday ‌it has reached a ⁠agreement ‌with U. President ‍Donald Trump's administration to ​cut ‌drug prices for Americans in exchange ⁠for exemptions ​from ​U.",
    "url": "https://finance.yahoo.com/news/johnson-johnson-reaches-deal-us-014424197.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "70c77120-03d8-3c87-8ad5-f86f6303d372",
      "content": {
        "id": "70c77120-03d8-3c87-8ad5-f86f6303d372",
        "contentType": "STORY",
        "title": "Johnson & Johnson reaches deal with US government to lower drug prices",
        "description": "",
        "summary": "Jan 8 () - Johnson & ​Johnson ‌said on Thursday ‌it has reached a ⁠agreement ‌with U. President ‍Donald Trump's administration to ​cut ‌drug prices for Americans in exchange ⁠for exemptions ​from ​U.",
        "pubDate": "2026-01-09T01:44:24Z",
        "displayTime": "2026-01-09T01:44:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/1b056a0c129ac97e83600ef696f7901e",
          "originalWidth": 800,
          "originalHeight": 534,
          "caption": "A Johnson & Johnson banner is displayed on the front of the New York Stock Exchange (NYSE) in New York City, in New York City, U.S., December 5, 2023.  REUTERS/Brendan McDermid",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CzfXYovqfIbswP.Z9BGwdw--~B/aD01MzQ7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/1b056a0c129ac97e83600ef696f7901e.cf.webp",
              "width": 800,
              "height": 534,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DRSzLSJK07LvlGTBx6DEkw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/1b056a0c129ac97e83600ef696f7901e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-reaches-deal-us-014424197.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-reaches-deal-us-014424197.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T01:24:00+00:00",
    "headline": "Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments",
    "summary": "NEW BRUNSWICK, N.J., January 09, 2026--Johnson & Johnson (NYSE: JNJ) (the \"Company\"), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs1.",
    "url": "https://finance.yahoo.com/news/johnson-johnson-reaches-agreement-u-012400796.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "7ec0e37a-8068-3581-95e0-2db7abc37d77",
      "content": {
        "id": "7ec0e37a-8068-3581-95e0-2db7abc37d77",
        "contentType": "STORY",
        "title": "Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments",
        "description": "",
        "summary": "NEW BRUNSWICK, N.J., January 09, 2026--Johnson & Johnson (NYSE: JNJ) (the \"Company\"), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs1.",
        "pubDate": "2026-01-09T01:24:00Z",
        "displayTime": "2026-01-09T01:24:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/4507ad9afe8e247ac161b41a52066c55",
          "originalWidth": 2404,
          "originalHeight": 224,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xt.GRZ4C.Vhn9ZGHRXvlng--~B/aD0yMjQ7dz0yNDA0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/4507ad9afe8e247ac161b41a52066c55.cf.webp",
              "width": 2404,
              "height": 224,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hI_Q7MUK2Jc87vVM6lSu9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4507ad9afe8e247ac161b41a52066c55.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-reaches-agreement-u-012400796.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-reaches-agreement-u-012400796.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T02:33:00+00:00",
    "headline": "Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices",
    "summary": "The agreement provides Johnson & Johnson’s pharmaceutical products an exemption from tariffs, the company said.",
    "url": "https://www.wsj.com/health/pharma/johnson-johnson-reaches-deal-with-trump-administration-to-lower-drug-prices-7bb39ff4?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "879f8ae7-8ec0-3bb1-a8c6-936359100e6b",
      "content": {
        "id": "879f8ae7-8ec0-3bb1-a8c6-936359100e6b",
        "contentType": "STORY",
        "title": "Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices",
        "description": "",
        "summary": "The agreement provides Johnson & Johnson’s pharmaceutical products an exemption from tariffs, the company said.",
        "pubDate": "2026-01-09T02:33:00Z",
        "displayTime": "2026-01-09T02:33:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/879f8ae7-8ec0-3bb1-a8c6-936359100e6b/johnson-johnson-reaches.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/d82dd8e8e85a01e57ff1e5caecf5bcce",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gvvFYiyrefo5gKYKETZ74g--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/d82dd8e8e85a01e57ff1e5caecf5bcce.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G66KHlRSGjXaMZKR0xE0rA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/d82dd8e8e85a01e57ff1e5caecf5bcce.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/johnson-johnson-reaches-deal-with-trump-administration-to-lower-drug-prices-7bb39ff4?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T11:03:28+00:00",
    "headline": "Stocks to Watch Friday: Intel, GM, Rio Tinto, Glencore",
    "summary": "↗️ Intel (INTC): President Trump said late Thursday he had \"just finished a great meeting\" with Intel CEO Lip-Bu Tan. The chipmaker's shares gained 2.5% in premarket trading. The U.S. has said it will convert around $9 billion in federal grants into a 10% equity stake in Intel.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-09-2026/card/stocks-to-watch-friday-gm-rio-tinto-glencore-w9Ro5pvtZqgLST9XJQ2k?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "9d003734-2869-3fb4-9337-02580e888f6e",
      "content": {
        "id": "9d003734-2869-3fb4-9337-02580e888f6e",
        "contentType": "STORY",
        "title": "Stocks to Watch Friday: Intel, GM, Rio Tinto, Glencore",
        "description": "",
        "summary": "↗️ Intel (INTC): President Trump said late Thursday he had \"just finished a great meeting\" with Intel CEO Lip-Bu Tan. The chipmaker's shares gained 2.5% in premarket trading. The U.S. has said it will convert around $9 billion in federal grants into a 10% equity stake in Intel.",
        "pubDate": "2026-01-09T11:03:28Z",
        "displayTime": "2026-01-09T11:03:28Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/9d003734-2869-3fb4-9337-02580e888f6e/stocks-to-watch-friday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7ebffeb957d46b7158f9bc3cd5da64c9",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ucpYXcbISAszAHSB_0yoRw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7ebffeb957d46b7158f9bc3cd5da64c9.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qkmUorqOFm17Zi4m8gto1w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7ebffeb957d46b7158f9bc3cd5da64c9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-09-2026/card/stocks-to-watch-friday-gm-rio-tinto-glencore-w9Ro5pvtZqgLST9XJQ2k?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "RTNTF"
            },
            {
              "symbol": "RTPPF"
            },
            {
              "symbol": "GLNCY"
            },
            {
              "symbol": "GM"
            },
            {
              "symbol": "INTC"
            },
            {
              "symbol": "RIO"
            },
            {
              "symbol": "GLCNF"
            },
            {
              "symbol": "FNMA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T10:10:00+00:00",
    "headline": "Johnson & Johnson Strikes Deal With White House to Lower Drug Prices",
    "summary": "Johnson & Johnson  has said it will lower the price of some medications sold to U.S. consumers, making it the latest pharmaceutical company to form a business agreement with the Trump administration.  “Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” Johnson & Johnson’s chief executive Joaquin Duato said in a statement late Thursday.  Johnson & Johnson also said it will participate in the proposed patient platform, TrumpRx.gov, which will allow patients to buy drugs at “significantly discounted rates.”",
    "url": "https://www.barrons.com/articles/johnson-johnson-drug-prices-trump-ac9c7111?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "f8f596d6-719b-328a-ae2e-9158775fd391",
      "content": {
        "id": "f8f596d6-719b-328a-ae2e-9158775fd391",
        "contentType": "STORY",
        "title": "Johnson & Johnson Strikes Deal With White House to Lower Drug Prices",
        "description": "",
        "summary": "Johnson & Johnson  has said it will lower the price of some medications sold to U.S. consumers, making it the latest pharmaceutical company to form a business agreement with the Trump administration.  “Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” Johnson & Johnson’s chief executive Joaquin Duato said in a statement late Thursday.  Johnson & Johnson also said it will participate in the proposed patient platform, TrumpRx.gov, which will allow patients to buy drugs at “significantly discounted rates.”",
        "pubDate": "2026-01-09T10:10:00Z",
        "displayTime": "2026-01-09T10:10:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f8f596d6-719b-328a-ae2e-9158775fd391/johnson-johnson-strikes.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/58dafcdadd562903692ad0190d979ae7",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nJkjt08zI6uU_WkqgFW73A--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/58dafcdadd562903692ad0190d979ae7.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OeE10rSQwJsFo15U3348.A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/58dafcdadd562903692ad0190d979ae7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/johnson-johnson-drug-prices-trump-ac9c7111?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "NVSEF"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T12:28:51+00:00",
    "headline": "HSBC lists 11 potential U.S. outperformers heading into earnings",
    "summary": "Investing.com -- HSBC has identified 11 U.S. stocks that could outperform as the fourth-quarter earnings season begins, highlighting companies with strong competitive positions, improving fundamentals and exposure to long-term themes.",
    "url": "https://finance.yahoo.com/news/hsbc-lists-11-potential-u-122851129.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "45e59105-3e9d-3905-9d79-58812348bf8b",
      "content": {
        "id": "45e59105-3e9d-3905-9d79-58812348bf8b",
        "contentType": "STORY",
        "title": "HSBC lists 11 potential U.S. outperformers heading into earnings",
        "description": "",
        "summary": "Investing.com -- HSBC has identified 11 U.S. stocks that could outperform as the fourth-quarter earnings season begins, highlighting companies with strong competitive positions, improving fundamentals and exposure to long-term themes.",
        "pubDate": "2026-01-09T12:28:51Z",
        "displayTime": "2026-01-09T12:28:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/hsbc-lists-11-potential-u-122851129.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/hsbc-lists-11-potential-u-122851129.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HSBC"
            },
            {
              "symbol": "ORCL"
            },
            {
              "symbol": "WMT"
            },
            {
              "symbol": "TMO"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T12:23:30+00:00",
    "headline": "J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts",
    "summary": "The New Jersey pharma will now offer some of its branded medicines on the US government-created DTC platform, TrumpRx.gov.",
    "url": "https://www.pharmaceutical-technology.com/news/johnson-johnson-mfn-drug-pricing-deal-branded-medicines/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "ff0d069b-ad61-3460-9dea-e4701a72a4c0",
      "content": {
        "id": "ff0d069b-ad61-3460-9dea-e4701a72a4c0",
        "contentType": "STORY",
        "title": "J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts",
        "description": "",
        "summary": "The New Jersey pharma will now offer some of its branded medicines on the US government-created DTC platform, TrumpRx.gov.",
        "pubDate": "2026-01-09T12:23:30Z",
        "displayTime": "2026-01-09T12:23:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/ef8ecfc6a5e4a78b276c45c9abb797cc",
          "originalWidth": 1024,
          "originalHeight": 700,
          "caption": "Johnson & Johnson has inked a drug pricing deal with the White House",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VzpCekl2eIipOcsoKH7yMQ--~B/aD03MDA7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/ef8ecfc6a5e4a78b276c45c9abb797cc.cf.webp",
              "width": 1024,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wtqFOx9uBfrdnx.jAIRW4Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/ef8ecfc6a5e4a78b276c45c9abb797cc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/johnson-johnson-mfn-drug-pricing-deal-branded-medicines/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/j-j-cuts-mfn-deal-122330905.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T10:23:00+00:00",
    "headline": "The Zacks Analyst Blog Highlights Johnson & Johnson, Caterpillar, Qualcomm, Fossil and Jones Soda",
    "summary": "Johnson & Johnson is gaining momentum as innovative medicines and a strengthening MedTech business support growth despite key patent headwinds.",
    "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-johnson-102300591.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "aaef1ac7-1995-3ad1-b435-e4b6ac6ac547",
      "content": {
        "id": "aaef1ac7-1995-3ad1-b435-e4b6ac6ac547",
        "contentType": "STORY",
        "title": "The Zacks Analyst Blog Highlights Johnson & Johnson, Caterpillar, Qualcomm, Fossil and Jones Soda",
        "description": "",
        "summary": "Johnson & Johnson is gaining momentum as innovative medicines and a strengthening MedTech business support growth despite key patent headwinds.",
        "pubDate": "2026-01-09T10:23:00Z",
        "displayTime": "2026-01-09T10:23:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/ddf3924b1ec6dc1f7af2495f083fa70e",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yn_lxkWVXLUUENv6USdHew--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ddf3924b1ec6dc1f7af2495f083fa70e.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8ZHaxfIQ5KVCurdgTeWsGA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ddf3924b1ec6dc1f7af2495f083fa70e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-johnson-102300591.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-johnson-102300591.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "QCOM"
            },
            {
              "symbol": "CAT"
            },
            {
              "symbol": "FOSL"
            },
            {
              "symbol": "JSDA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T12:44:00+00:00",
    "headline": "Here's What We Expect From AbbVie's Immunology Segment in Q4",
    "summary": "ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity.",
    "url": "https://finance.yahoo.com/news/heres-expect-abbvies-immunology-segment-124400845.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "56543896-1532-3429-ae94-e3a17404ce99",
      "content": {
        "id": "56543896-1532-3429-ae94-e3a17404ce99",
        "contentType": "STORY",
        "title": "Here's What We Expect From AbbVie's Immunology Segment in Q4",
        "description": "",
        "summary": "ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity.",
        "pubDate": "2026-01-09T12:44:00Z",
        "displayTime": "2026-01-09T12:44:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OQG3.5Wd9P9R69q2rhm9rA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pBlncPVBhEXpjxtBDlEOsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-expect-abbvies-immunology-segment-124400845.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-expect-abbvies-immunology-segment-124400845.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": null
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T11:55:14+00:00",
    "headline": "Earnings Preview: What to Expect From Kenvue’s Report",
    "summary": "Kenvue is gearing to release its fourth-quarter results shortly, and analysts expect its earnings to fall in low-double-digits.",
    "url": "https://www.barchart.com/story/news/36964709/earnings-preview-what-to-expect-from-kenvues-report",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "52680d48-a67d-39f3-8051-64d7b1e8f361",
      "content": {
        "id": "52680d48-a67d-39f3-8051-64d7b1e8f361",
        "contentType": "STORY",
        "title": "Earnings Preview: What to Expect From Kenvue’s Report",
        "description": "",
        "summary": "Kenvue is gearing to release its fourth-quarter results shortly, and analysts expect its earnings to fall in low-double-digits.",
        "pubDate": "2026-01-09T11:55:14Z",
        "displayTime": "2026-01-09T11:55:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/378e6cbace0012d5d229fc23c2ce4ff6",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "Kenvue Inc phone and webpage- by T_Schneider via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bmtb8H7ppFK2n0sZISRyzA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/378e6cbace0012d5d229fc23c2ce4ff6.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.g9n77SNCLmlU5XPe9KQgA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/378e6cbace0012d5d229fc23c2ce4ff6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/36964709/earnings-preview-what-to-expect-from-kenvues-report",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/earnings-preview-expect-kenvue-report-115514480.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]